Ird Luxturna denied for failing step therapy by Cigna?

Cigna's specific coverage criteria for ird luxturna are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Cigna Issued a Step-Therapy Denial for Luxturna — and Why It Is Likely Overturnable

Step-therapy (also called "fail-first") requirements generally demand that a patient try lower-cost or less-complex treatments before an insurer will cover the requested therapy. For Luxturna — a gene therapy for an inherited retinal dystrophy — a step-therapy denial is clinically inappropriate in most cases because: (a) the condition is genetic and structural, not amenable to pharmacologic substitution; and (b) there is no FDA-approved alternative that addresses the same molecular mechanism. Cigna is required under most state laws and federal guidance to grant a step-therapy exception when the required alternative is medically contraindicated, ineffective, or simply does not exist for the condition.

## Federal and State Appeal Rights

Under ACA §2719, you may file an internal appeal followed by an independent external review. Under ERISA §503, employer plan members have full-and-fair review rights including access to the clinical criteria applied. The external review window is typically 4 months from the final internal denial. Many states have enacted specific step-therapy exception laws that apply to fully insured plans — your prescriber and appeal advocate should cite the applicable state statute in the appeal letter. If vision deterioration is ongoing, expedited external review is available.

## Concrete Appeal Steps

1. Obtain the denial letter and identify precisely which "step" therapy Cigna claims you must try first. 2. Download Cigna's step-therapy policy and their Luxturna coverage policy from cigna.com. 3. Have the treating specialist document in writing why no required step therapy is an appropriate substitute for this patient's specific genetic condition. 4. File the internal appeal citing step-therapy exception criteria. 5. If denied internally, file for independent external review immediately.

## Documentation to Gather

• Genetic and diagnosis confirmation: Lab report confirming the specific mutation and full ophthalmologic workup documenting the inherited retinal dystrophy diagnosis.
• Clinical explanation of why step alternatives do not apply: The prescriber must explain, for each required step therapy, that it either does not treat the genetic mechanism of this condition, is not FDA-approved for this indication, or was already tried with documented failure — whichever applies.
• Specialty-society guideline reference: A statement from the prescriber citing the relevant specialty organization's (e.g., American Academy of Ophthalmology) guidance on management of inherited retinal dystrophies, which can reinforce that no valid step-therapy alternative exists.
• Retinal function assessment: Current visual function testing showing the patient still has sufficient retinal viability to benefit, per the FDA label.

## Criteria-Mapping Structure

For each step-therapy requirement in Cigna's policy, write a one-sentence response that either (a) identifies the exact chart documentation showing the step was tried and failed, or (b) explains on clinical grounds — citing the FDA label and guideline organization — why the step does not apply. Pair this with the prescriber's letter and the genetic report. External reviewers consistently overturn step-therapy denials for genetic therapies when no clinically equivalent alternative exists.